Systematic review of 7 studies (725 patients with Parkinson's disease): subcutaneous levodopa/carbidopa or foslevodopa/foscarbidopa infusion vs oral levodopa/carbidopa reduced daily OFF-time by 1.98 h but increased adverse events, mostly infusion-site.
Meta-analysisn = 725
Burton et al. Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis